3D MEDICINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.06 HKD | +8.28% |
|
+11.36% | -7.59% |
| 29/03 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
| 28/03 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 60.26 470.58 5.03K | Sales 2022 | 567.39 4.43K 47.32K | Capitalization | 8.38B 65.46B 699B |
|---|---|---|---|---|---|
| Net income 2021 | -1.43B -11.2B -120B | Net income 2022 | -1.02B -8B -85.39B | EV / Sales 2021 * | - |
| Net Debt 2021 | 2.37B 18.48B 197B | Net cash position 2022 | 766M 5.98B 63.9B | EV / Sales 2022 | 1,34,23,339 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.67
x | Employees | 198 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +8.28% | ||
| 1 week | +11.36% | ||
| Current month | +7.95% | ||
| 1 month | +26.07% | ||
| 3 months | +19.66% | ||
| 6 months | -19.04% | ||
| Current year | -7.59% |
1 week
6.09
7.55
1 month
5.177.55
Current year
5.178.45
1 year
4.68131.50
3 years
4.68131.50
5 years
4.68131.50
10 years
4.68131.50
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 01/14/01 |
Jing Zhang
DFI | Director of Finance/CFO | 50 | 28/20/28 |
Zhi Qiang Xue
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tat Pang Lin
BRD | Director/Board Member | 67 | 01/22/01 |
Xin Guang Liu
BRD | Director/Board Member | 63 | 25/21/25 |
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 01/14/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 7.06 | +8.28% | 4,557,000 |
| 13/24/13 | 6.52 | -3.41% | 881,500 |
| 10/24/10 | 6.75 | 0.00% | 1,258,500 |
| 09/24/09 | 6.75 | +10.66% | 2,857,500 |
| 08/24/08 | 6.1 | -3.79% | 722,000 |
Delayed Quote Hong Kong S.E., May 14, 2024 at 01:38 pm IST
More quotes
3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.59% | 205M | |
| +7.51% | 111B | |
| +11.31% | 106B | |
| -12.55% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.78% | 16.81B | |
| +37.29% | 12.54B | |
| -24.05% | 8.09B |
- Stock Market
- Equities
- 1244 Stock